Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection

被引:17
作者
Liu, Y [1 ]
Mullins, JI
Mittler, JE
机构
[1] Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA
关键词
HIV-1; natural selection; waiting time; CTL escape mutant;
D O I
10.1016/j.virol.2005.11.036
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The failure of HIV-1 to escape at some cytotoxic T-lymphocyte (CTL) epitopes has generally been explained in terms of viral fitness costs or ineffective or attenuated CTL responses. Relatively little attention has been paid to the evolutionary time required for escape mutants to be detected. This time is significantly affected by selection, mutation rates, the presence of other advantageous mutations, and the effective population size of HIV-1 in vivo (typically estimated to be similar to 10(3) in chronically infected patients, though one study has estimated it to be similar to 10(5)). Here, we use a forward simulator with experimentally estimated HIV-1 parameters to show that these delays can be substantial. For an effective population size of 10(3), even highly advantageous mutants (s = 0.5) may not be detected for a couple of years in chronically infected patients, while moderately advantageous escape mutants (s = 0.1) may not be detected for up to 10 years. Even with an effective population size of 10(5), a moderately advantageous escape mutant (s = 0.1) may not be detected in the population within 2 years if it has to compete with other selectively advantageous mutants. Stochastic evolutionary forces, therefore, in addition to viral fitness costs and ineffective or attenuated CTL responses, must be taken into account when assessing the selection of CTL escape mutations. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:140 / 146
页数:7
相关论文
共 40 条
[11]   HIV and SIVCTL escape: Implications for vaccine design [J].
Goulder, PJR ;
Watkins, DI .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (08) :630-640
[12]   Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection [J].
Goulder, PJR ;
Altfeld, MA ;
Rosenberg, ES ;
Nguyen, T ;
Tang, YH ;
Eldridge, RL ;
Addo, MM ;
He, SQ ;
Mukherjee, JS ;
Phillips, MN ;
Bunce, M ;
Kalams, SA ;
Sekaly, RP ;
Walker, BD ;
Brander, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (02) :181-193
[13]   Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS [J].
Goulder, PJR ;
Phillips, RE ;
Colbert, RA ;
McAdam, S ;
Ogg, G ;
Nowak, MA ;
Giangrande, P ;
Luzzi, G ;
Morgan, B ;
Edwards, A ;
McMichael, AJ ;
RowlandJones, S .
NATURE MEDICINE, 1997, 3 (02) :212-217
[14]   Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection [J].
Hay, CM ;
Ruhl, DJ ;
Basgoz, NO ;
Wilson, CC ;
Billingsley, JM ;
DePasquale, MP ;
D'Aquila, RT ;
Wolinsky, SM ;
Crawford, JM ;
Montefiori, DC ;
Walker, BD .
JOURNAL OF VIROLOGY, 1999, 73 (07) :5509-5519
[15]  
Kim Y, 2003, GENETICS, V164, P389
[16]   TEMPORAL ASSOCIATION OF CELLULAR IMMUNE-RESPONSES WITH THE INITIAL CONTROL OF VIREMIA IN PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 SYNDROME [J].
KOUP, RA ;
SAFRIT, JT ;
CAO, YZ ;
ANDREWS, CA ;
MCLEOD, G ;
BORKOWSKY, W ;
FARTHING, C ;
HO, DD .
JOURNAL OF VIROLOGY, 1994, 68 (07) :4650-4655
[17]   Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA [J].
Leslie, A ;
Kavanagh, D ;
Honeyborne, I ;
Pfafferott, K ;
Edwards, C ;
Pillay, T ;
Hilton, L ;
Thobakgale, C ;
Ramduth, D ;
Draenert, R ;
Le Gall, S ;
Luzzi, G ;
Edwards, A ;
Brander, C ;
Sewell, AK ;
Moore, S ;
Mullins, J ;
Moore, C ;
Mallal, S ;
Bhardwaj, N ;
Yusim, K ;
Phillips, R ;
Klenerman, P ;
Korber, B ;
Kiepiela, P ;
Walker, B ;
Goulder, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (06) :891-902
[18]   Molecular clock-like evolution of human immunodeficiency virus type 1 [J].
Liu, Y ;
Nickle, DC ;
Shriner, D ;
Jensen, MA ;
Learn, GH ;
Mittler, JE ;
Mullins, JI .
VIROLOGY, 2004, 329 (01) :101-108
[19]   Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line [J].
Mansky, LM .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (04) :307-314
[20]   A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-Cell decay in vivo [J].
Markowitz, M ;
Louie, M ;
Hurley, A ;
Sun, E ;
Di Mascio, M .
JOURNAL OF VIROLOGY, 2003, 77 (08) :5037-5038